Compare Lululemon Athletica Inc (LULU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Lululemon stock trades at $94.34, near its 52-week low, reflecting a 54% decline year-to-date amid growth concerns and securities fraud investigations. The technical picture is bearish, with the stock below key moving averages. Fundamentally, the company maintains strong profitability with a 56.11% gross margin and 12.78% net margin, but revenue growth has slowed, and Q3 2026 earnings are pending. Analyst consensus is mixed, with a Hold rating predominant and a $97.67 price target.

The outlook is cautious due to competitive pressures, governance scrutiny, and potential legal liabilities. While valuation metrics like a P/E of 7.76 appear attractive, near-term risks from weakening fundamentals and negative sentiment may limit upside. Recovery hinges on reversing revenue trends and resolving legal overhangs, making the stock speculative for now.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.